公开(公告)号：US20050065075A1

公开(公告)日：2005-03-24

申请号：US10478811

申请日：2002-05-31

申请人： John Erickson ,  Dominique Bridon ,  Martin Robitaille ,  Grant Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

发明人： John Erickson ,  Dominique Bridon ,  Martin Robitaille ,  Grant Krafft ,  Dong Xie ,  Elena Afonina ,  Jun Liang ,  Sandra DeMeyer

IPC分类号： A61K47/48 ,  A61K38/00 ,  A61P31/14 ,  A61P31/18 ,  C07K1/113 ,  C07K14/00 ,  C07K14/16 ,  A61K38/16 ,  C07K14/47

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K2319/00 ,  C12N2740/16122

摘要： The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

摘要翻译： 本发明涉及作为病毒感染抑制剂和/或显示抗融合性质的C34肽衍生物。 特别地，本发明涉及具有长期持续时间的针对人免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV））具有抑制活性的C34衍生物 的治疗各自病毒感染的作用。

公开(公告)号：US20060166275A1

公开(公告)日：2006-07-27

申请号：US11130566

申请日：2005-05-16

申请人： Grant Krafft ,  William Klein ,  Brett Chromy ,  Mary Lambert ,  Caleb Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

发明人： Grant Krafft ,  William Klein ,  Brett Chromy ,  Mary Lambert ,  Caleb Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

IPC分类号： A61K38/17 ,  C07K14/47 ,  G01N33/53 ,  C07H21/04 ,  C12P21/06

CPC分类号： C07K14/4711 ,  A61K38/00

摘要： The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid β peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

公开(公告)号：US20070213512A1

公开(公告)日：2007-09-13

申请号：US11686570

申请日：2007-03-15

申请人： Grant Krafft ,  William Klein ,  Kirsten Viola ,  Mary Lambert ,  Todd Pray ,  Ray Lowe

发明人： Grant Krafft ,  William Klein ,  Kirsten Viola ,  Mary Lambert ,  Todd Pray ,  Ray Lowe

IPC分类号： C07K14/00

CPC分类号： C07K14/4711 ,  A61K39/0007 ,  C07K16/18

摘要： The present invention provides amyloid β peptide assemblies composed of at least three amyloid β peptide subunits, wherein at least one of the amyloid β peptide subunits is an amyloid β peptide analog. The invention further relates to metal complexes of amyloid β peptide assemblies and the use of amyloid β peptide assemblies as vaccines and in the identification of agents that modulate assembly of the amyloid β peptide subunits.

摘要翻译： 本发明提供了由至少三个淀粉样蛋白β肽亚基组成的淀粉样蛋白β肽组件，其中淀粉样蛋白β肽亚基中的至少一个是淀粉样蛋白β肽类似物。 本发明还涉及淀粉样蛋白β肽组件的金属络合物和淀粉样蛋白β肽组件作为疫苗的用途，以及用于鉴定调节淀粉状蛋白β肽亚基的组装的试剂。

公开(公告)号：US20070264669A1

公开(公告)日：2007-11-15

申请号：US11747324

申请日：2007-05-11

申请人： Wei-Qin Zhao ,  Grant Krafft ,  William Klein

发明人： Wei-Qin Zhao ,  Grant Krafft ,  William Klein

IPC分类号： G01N33/53 ,  A61K38/28

CPC分类号： G01N33/74 ,  A61K38/28 ,  G01N33/5008 ,  G01N2500/00

摘要： The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric Aβ peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric Aβ peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric Aβ peptide assemblies, also known as ADDLs, and ADDL-related assemblies.

摘要翻译： 本发明涉及从神经元和非神经元细胞周围的环境中增强可溶性寡聚Aβ肽组件的细胞吸收和清除的方法。 通过增强胰岛素受体信号传导的药物来实现低聚Abeta肽组装体摄取和清除。 这种ADDL摄取增强剂代表用于治疗性治疗和/或预防性治疗包括阿尔茨海默氏病，唐氏综合症等的疾病的有效的抗ADDL治疗剂，其中受损的神经细胞功能与形成和/或活性相关 的可溶性低聚Abeta肽组件，也称为ADDL和ADDL相关组件。

公开(公告)号：US20060178302A1

公开(公告)日：2006-08-10

申请号：US11100212

申请日：2005-04-06

申请人： Grant Krafft ,  William Klein ,  Brett Chromy ,  Mary Lambert ,  Caleb Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

发明人： Grant Krafft ,  William Klein ,  Brett Chromy ,  Mary Lambert ,  Caleb Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

IPC分类号： A61K38/17 ,  C07K14/47

CPC分类号： C07K14/4711 ,  A61K38/00 ,  A61K2039/505

摘要： The invention provides amyloid beta-derived dementing ligands (ADDLs) that comprise amyloid β protein assembled into globular non-fibrillar oligomeric structures capable of activating specific cellular processes. The invention also provides methods for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDLs, and modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

摘要翻译： 本发明提供了包含淀粉样蛋白β蛋白的淀粉样蛋白β衍生的蜕膜配体（ADDL），其组装成能够激活特定细胞过程的球状非纤维寡聚结构。 本发明还提供了用于测定ADDL的形成，存在，受体蛋白结合和细胞活性的方法，以及阻断ADDL的形成或活性的化合物以及鉴定这些化合物的方法。 本发明进一步提供使用ADDL的方法，以及调节ADDL形成和/或活性，特别是在学习和/或记忆障碍的治疗中。

公开(公告)号：US20070218499A1

公开(公告)日：2007-09-20

申请号：US11571532

申请日：2005-07-05

申请人： Mary Lambert ,  Pauline Velasco ,  Lei Chang ,  Kirsten Viola ,  Sara Fernandez ,  Pascale Lacor ,  Daliya Khuon ,  Yuesong Gong ,  William Klein ,  Grant Krafft

发明人： Mary Lambert ,  Pauline Velasco ,  Lei Chang ,  Kirsten Viola ,  Sara Fernandez ,  Pascale Lacor ,  Daliya Khuon ,  Yuesong Gong ,  William Klein ,  Grant Krafft

IPC分类号： G01N33/53 ,  C07K16/18

CPC分类号： C07K16/18 ,  C07K2317/76 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

摘要： Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.

摘要翻译： 本文公开了与淀粉样蛋白β（Abeta）的可溶性低聚物以高特异性结合的抗体以及使用这些抗体的方法。 抗体能够区分阿尔茨海默病（AD）和对照人脑提取物。 抗体鉴定AD脑切片中的内源性Aβ寡聚物，并且还结合培养的海马细胞上的Abeta寡聚物。 抗体中和溶液中产生的内源性Aβ低聚物和Abeta寡聚体。

公开(公告)号：US20070048312A1

公开(公告)日：2007-03-01

申请号：US11496149

申请日：2006-07-31

申请人： William Klein ,  Grant Krafft ,  Mary Lambert ,  Kirsten Viola ,  Brett Chromy ,  Lei Chang

发明人： William Klein ,  Grant Krafft ,  Mary Lambert ,  Kirsten Viola ,  Brett Chromy ,  Lei Chang

IPC分类号： A61K39/395

CPC分类号： G01N33/6896 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4711 ,  C07K16/18 ,  G01N2333/4709 ,  G01N2800/2821

摘要： The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.

摘要翻译： 本发明包括结合淀粉样蛋白β衍生的扩散配体（ADDL）的抗体。 ADDL包含组装成能够激活特异性细胞过程的可溶性，球状，非纤维状，寡聚结构的淀粉样蛋白β蛋白。